BRAF and cancer: These inhibitors bind to both protomers of the RAF dimer, stabilizing the αC-helix in the IN position (αC-helix IN/DFG-OUT RAF inhibitors or type 2) [15], and are currently under preclinical and clinical evaluation in solid BRAF-mutant cancers, including lung cancer (Table 1).